Novel therapies for chronic lymphocytic leukemia: A Canadian perspective

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 11, 2015, Pages 627-634.e5

  Owen, Carolyn ^a   Assouline, Sarit ^b   Kuruvilla, John ^c   Uchida, Cassandra ^d   Bellingham, Catherine ^d   Sehn, Laurie ^e  

^a FOOTHILLS HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d New Evidence   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chronic lymphocytic leukemia; Duvelisib; Ibrutinib; Idelalisib; Monoclonal antibodies; Obinutuzumab; Small molecule inhibitors; Venetoclax

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; DUVELISIB; IBRUTINIB; IDELALISIB; METHYLPREDNISOLONE; OBINUTUZUMAB; OFATUMUMAB; PREDNISONE; PROTEIN P53; RITUXIMAB; VENETOCLAX;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLEEDING; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEVER; HUMAN; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; PNEUMONIA; RECOMMENDED DRUG DOSE; REVIEW; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; EXPERT WITNESS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULARLY TARGETED THERAPY; MORTALITY; TREATMENT OUTCOME;

EXPERT TESTIMONY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84947031389     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.07.649     Document Type: Note

References (52)

1. M. Hallek, K. Fischer, G. Fingerle-Rowson, and et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 2010 1164 1174
2. V. Goede, and M. Hallek Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly Drugs Aging 28 2011 163 176
3. H. Dohner, S. Stilgenbauer, A. Benner, and et al. Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 2000 1910 1916
4. P. Shindiapina, J.R. Brown, and A.V. Danilov A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53 Br J Haematol 167 2014 149 161
5. T. Shanafelt Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers Hematol Am Soc Hematol Educ Program 2013 2013 158 167
6. Eichhorst B, Fink A, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). American Society of Hematology Annual Meeting Abstracts 2014:19.
7. D. Catovsky, S. Richards, E. Matutes, and et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial Lancet 370 2007 230 239
8. W.U. Knauf, T. Lissichkov, A. Aldaoud, and et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia J Clin Oncol 27 2009 4378 4384
9. A. Wiestner Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia Blood 120 2012 4684 4691
10. L. Pleyer, A. Egle, T.N. Hartmann, and et al. Molecular and cellular mechanisms of CLL: novel therapeutic approaches Nat Rev Clin Oncol 6 2009 405 418
11. P. Boross, and J.H. Leusen Mechanisms of action of CD20 antibodies Am J Cancer Res 2 2012 676 690
12. E. Decaup, C. Jean, C. Laurent, and et al. Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model Blood Cancer J 3 2013 e131
13. S. Herter, F. Herting, O. Mundigl, and et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models Mol Cancer Ther 12 2013 2031 2042
14. S. Cang, N. Mukhi, K. Wang, and et al. Novel CD20 monoclonal antibodies for lymphoma therapy J Hematol Oncol 5 2012 64
15. M.S. Czuczman, and S.A. Gregory The future of CD20 monoclonal antibody therapy in B-cell malignancies Leuk Lymphoma 51 2010 983 994
16. W. Alduaij, A. Ivanov, J. Honeychurch, and et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies Blood 117 2011 4519 4529
17. J. Honeychurch, W. Alduaij, M. Azizyan, and et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway Blood 119 2012 3523 3533
18. V. Goede, K. Fischer, R. Busch, and et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions N Engl J Med 370 2014 1101 1110
19. V. Goede, K. Fischer, A. Engelke, and et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study Leukemia 29 2015 1602 1604
20. P. Hillmen, T. Robak, A. Janssens, and et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial Lancet 385 2015 1873 1883
21. T. Robak, A. Dmoszynska, P. Solal-Céligny, and et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia J Clin Oncol 28 2010 1756 1765
22. S. Fiorcari, W.S. Brown, B.W. McIntyre, and et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells PLoS One 8 2013 e83830
23. R.R. Furman, J.P. Sharman, S.E. Coutre, and et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia N Engl J Med 370 2014 997 1007
24. Eradat HA, Ghia P, O'Brien SM, et al. Health-related quality of life (HRQL) impact of idelalisib in patients with relapsed chronic lymphocytic leukemia: phase 3 results [abstract P252]. Paper presented at: 19th Congress of the European Hematology Association; June 12-15, 2014 in Milan, Italy.
25. Coutre SE, Furman RR, Sharman JP, et al. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL [abstract S704]. Paper presented at: 19th Congress of the European Hematology Association; June 12-15, 2014 in Milan, Italy.
26. Stilgenbauer S, Coutre SE, Furman RR, et al. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract S1341]. Paper presented at: 19th Congress of the European Hematology Association; June 12-15, 2014 in Milan, Italy.
27. S. O'Brien, N. Lamanna, T.J. Kipps, and et al. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naive patients ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) Blood 124 2014 1994
28. S.E. Herman, A.L. Gordon, E. Hertlein, and et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Blood 117 2011 6287 6296
29. M.F. de Rooij, A. Kuil, C.R. Geest, and et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia Blood 119 2012 2590 2594
30. J.C. Byrd, R.R. Furman, S.E. Coutre, and et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N Engl J Med 369 2013 32 42
31. J.C. Byrd, J.R. Brown, S. O'Brien, and et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 371 2014 213 223
32. J.R. Brown, P. Hillmen, S. O'Brien, and et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma Blood 124 2014 3331
33. W.G. Wierda, T.J. Kipps, J. Mayer, and et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia J Clin Oncol 28 2010 1749 1755
34. S. O'Brien, R.R. Furman, S.E. Coutre, and et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial Lancet Oncol 15 2014 48 58
35. S. Kamel, L. Horton, L. Ysebaert, and et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation Leukemia 29 2015 783 787
36. M. Levade, E. David, C. Garcia, and et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions Blood 124 2014 3991 3995
37. PrIMBRUVICA™ (Ibrutinib). Product monograph 2014 Janssen Inc Toronto, Ontario
38. A.J. Souers, J.D. Leverson, E.R. Boghaert, and et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat Med 19 2013 202 208
39. K. Brinkmann, and H. Kashkar Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell Death Dis 5 2014 e1098
40. J.F. Seymour, M.S. Davids, J.M. Pagel, and et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-aumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) Blood 122 2013 872
41. A.W. Roberts, S. Ma, D.M. Brander, and et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Blood 124 2014 325
42. Roberts AW, Ma S, Brander D, et al. ABT-199 (GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocyitc leukemia: interim results of a phase 1b study [abstract S703]. Paper presented at: 19th Congress of the European Hematology Association; June 12-15, 2014 in Milan, Italy.
43. D.G. Winkler, K.L. Faia, J.P. DiNitto, and et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models Chem Biol 20 2013 1364 1374
44. S. O'Brien, M. Patel, B.S. Kahl, and et al. Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia Blood 124 2014 3334
45. S. Böttcher, M. Ritgen, K. Fischer, and et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial J Clin Oncol 30 2012 980 988
46. J.A. Jones, and J.C. Byrd How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 123 2014 1455 1460
47. J.A. Woyach, R.R. Furman, T.M. Liu, and et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib N Engl J Med 370 2014 2286 2294
48. P.A. Thompson, W.G. Wierda, A. Ferrajoli, and et al. Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens Blood 124 2014 22
49. K.J. Maddocks, A.S. Ruppert, G. Lozanski, and et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia JAMA Oncol 1 2015 80 87
50. P. Strati, M.J. Keating, S.M. O'Brien, and et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL Blood 123 2014 3727 3732
51. J.C. Byrd, R.R. Furman, S.E. Coutre, and et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib Blood 125 2015 2497 2506
52. P. Dreger, J. Schetelig, N. Andersen, and et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 124 2014 3841 3849